Board of Directors

 

Rupert Lywood, Chairman

Rupert is a Chartered Accountant who qualified with Robson Rhodes. Latterly he specialised in structured finance and venture capital. Rupert has spent the last 25 years founding and building businesses in the energy, information, finance, medical, and media sectors – including co-founding and chairing a multi-billion European energy business which he sold to International Power in 2007. He remains active in all these sectors and in addition is currently focused on creating and delivering literacy programs in both the Developed and Developing World.

 

Neil Laycock, Chief Executive Officer

Neil joined Origin in December 2017. Neil is an accomplished leader in the health and technology sector, having previously been the CEO of the Internet Service Provider PlusNet and latterly the MD of www.patient.info (the UK’s largest private free online health resource that receives over 2 million unique hits per day) Neil was also the MD of EMIS Ltd (the largest UK software vendor in primary care hosting over 39million patient records)

 

Dr. Colin Ferrett Medical Director

Colin is a consultant radiologist at Oxford University Hospital, having trained at Queen’s University, Belfast, UC San Diego and UC Stanford in medicine and radiology. He is a co-inventor of the OriCol™ balloon and founder of Origin Sciences. Involved in diagnostics, staging and research of CRC for 20 years, he is the PI of the recent successful trial. He has collected samples from several hundred patients with suspected colorectal cancer.

 

Stuart Lawson, Finance Director

Stuart is CEO of the private investment group headed by Animatrix Capital LLP, which holds a broad range of investments with the core focus being early stage medical research. Stuart serves as CFO of group members Loxbridge Research LLP, Premaitha Health Ltd and Agalimmune Ltd. He qualified as a Chartered Accountant before working as a Manager at KPMG. He then worked as a Finance Director before moving to and becoming Group CFO and European MD with a LSE fully quoted manufacturing company; during his time he led them through 16 Global acquisitions. Stuart is also a Trustee for the children’s charity, The Safepoint Trust, and serves as Chairman of a Mergers & Acquisitions Company based in Istanbul.

 

Per Aniansson, Director

Per Aniansson is currently an Investment Director at Fouriertransform AB, a Swedish Venture Capital/Private Equity company. He holds an MSc Engineering Physics from Chalmers University of Technology and an MBA from INSEAD. Prior to joining Fouriertransform Mr Aniansson gained experience in venture capital investments and other major investments from positions with Industrivärden, Siemens and Innovationskapital. Mr Aniansson was also a Management consultant with Accenture and Arthur D Little, mainly with a focus in the Pharma and Medtech business. He is on the board of a number of technology companies of which two are in the UK, Origin Sciences Ltd and Star Syringe Ltd.

 

Graham Griffiths Non-Executive Director

Graham qualified as a solicitor in 2005, before moving to co-found technology company MET that was subsequently sold to a group of private investors. He was an investment fund manager at Matrix Securities and for 9 years contributed across the portfolio of life sciences companies within the Animatrix Capital group. Graham’s focus was on developing early stage products and companies targeting the diagnosis and treatment of cancer and infectious diseases. Graham holds a BA Hons degree in Law with French from Newcastle University.

Now as a Non-Executive Director of Origin Sciences he mainly is involved in developing in vitro diagnostic tests to detect colorectal cancer (in a screening population) and inflammatory bowel disease, by analysis of human DNA, the microbiome and proteins. Commercialisation of OriCol medical device for sampling the gut mucosa.